VcMMAE

    • Catalog No.:MC0559
      • CasNo:
      • 646502-53-6
      • MolecularFormula:
      • C68H105N11O15
      • Purity:
      • 99.11%
      • Target:
      • Drug-Linker Conjugates for ADC
      • IC50:
      • No data
      • In Vitro:
      • Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2].
      • In Vivo:
      • Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models[2].
      • Fields:
      • VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
      • Specificity:
      • Target: Drug-Linker Conjugates for ADC. Fields: VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via th
      • Concentration:
      • 99.11%
      • Storage Stability:
      • 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
      • Other Name:
      • VC-MMAE,Vc MMAE
      • MolecularWeight(Da):
      • 1316.63
      • References:
      • [1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. [2]. Lisa Buckel, et al. Tumor radiosensitization
      • Products Images